Medicated intrauterine devices for contraception and their therapeutic effects

  title={Medicated intrauterine devices for contraception and their therapeutic effects},
  author={Tapani Luukkainen and P{\"a}ivi I. Pakarinen},
  journal={Expert Review of Obstetrics \& Gynecology},
There is currently one medicated intrauterine device on the market for clinical use; Mirena®, which releases levonorgestel. Mirena has widely replaced Progestasert®, which released progesterone. The levonorgestel released by Mirena into the uterine cavity not only increases the contraceptive efficacy of the intrauterine device but also has many beneficial effects on women’s health. This article reviews the contraceptive efficacy of this medicated intrauterine device, the health effects of… 
2 Citations
Intrauterine contraception: the pendulum swings back.
Intrauterine contraception is the most widely used method of reversible fertility regulation in the world and it's role will expand as new devices and systems are developed and as old biases among clinicians and women are erased.
Abstracts from Recent or Upcoming Scientific Meetings 49 Access to Contraceptives Target of Comstock Act Family Planning Advocates Turn to the Courts for Relief U.s. Supreme Court Issues Landmark Decision in Griswold v. Connecticut a Concurring Opinion by Justice
s from Recent or Upcoming Scientific Meetings 49 The Year in Review 57 Photo Highlights from the 2007 Yale Ob/Gyn Residents’ Research Day 65 Photo Highlights from the First YOGS Gathering at ACOG in


Contraceptive and Therapeutic Effects of the Levonorgestrel Intrauterine System: An Overview
  • J. Jensen
  • Medicine
    Obstetrical & gynecological survey
  • 2005
This review article provides an overview of the LNG IUS and addresses the following topics: mechanisms of action, contraceptive efficacy, changes in bleeding patterns, principal safety issues, potential noncontraceptive benefits, and implications for women’s reproductive health.
Therapeutic use of the LNG IUS, and counseling.
Use of LNG-releasing intrauterine system (LNG IUS) in treatment and prevention of anemia and in the therapy of menorrhagia and dysmenorrhea and the antiproliferative effect of the LNG I US on the endometrium is discussed.
Endometrial Morphology During Long‐Term Use of Levonorgestrel‐Releasing Intrauterine Devices
Intrauterine release of Levonorgestrel resulted in endo-metrial glandular atrophy and decidualized stroma and inflammation and necrosis were seen as local signs of IUD use.
Progestin-releasing intrauterine systems.
The levonorgestrel-releasing intrauterine system (LNG IUS) is an effective method for contraception, and the risk of pelvic inflammatory disease is reduced, because of reduced menstrual blood loss, endometrial suppression, and thickening of the cervical mucus.
Randomized comparison of levonorgestrel- and copper-releasing intrauterine systems immediately after abortion, with 5 years' follow-up.
Mirena was more effective and the rate of adverse events was lower than with NovaT, and special attention should be paid to the insertion procedure when carried out at the time of abortion.
The levonorgestrel-releasing intrauterine device.
  • J. Toivonen
  • Medicine
    Advances in contraceptive delivery systems : CDS
  • 1994
Levonorgestrel generally has an effect on the ovaries just during the 1st year of use, which causes scanty and thick cervical mucus, its major contraceptive mode of action.
Endometrial morphology of women using a d-norgestrel-releasing intrauterine device.
Endometrial biopsies were obtained from 12 volunteers treated with d-norgestrel-releasing intrauterine devices with two different release rate and changes similar to those observed during the luteal phase and early pregnancy could be seen in the tubal epithelium.
Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study.
The safety and acceptability of the LNG IUS for contraception was observed to be as good as with OCs, with a high continuation rate.
Use of the Levonorgestrel-Releasing Intrauterine System and Breast Cancer
The results suggest that the use of the levonorgestrel-releasing intrauterine system is not associated with an increased risk of breast cancer.
Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
Preliminary findings suggest that the levonorgestrel-releasing intrauterine contraceptive device is a useful alternative mode of progestin administration for certain selected women receiving estrogen replacement therapy.